|
ERH expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.93538999999632E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.419400E-04 |
| Normal-vs-Stage2 |
1.180040E-02 |
| Normal-vs-Stage3 |
2.18260000000026E-05 |
| Normal-vs-Stage4 |
3.22340000247223E-08 |
| Stage1-vs-Stage2 |
7.781200E-01 |
| Stage1-vs-Stage3 |
2.325600E-01 |
| Stage1-vs-Stage4 |
2.237900E-03 |
| Stage2-vs-Stage3 |
3.001600E-01 |
| Stage2-vs-Stage4 |
2.425800E-02 |
| Stage3-vs-Stage4 |
9.952300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.80609000000054E-05 |
| Normal-vs-AfricanAmerican |
2.556200E-04 |
| Normal-vs-Asian |
2.476700E-03 |
| Caucasian-vs-AfricanAmerican |
3.143000E-01 |
| Caucasian-vs-Asian |
6.248000E-01 |
| AfricanAmerican-vs-Asian |
2.185200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.52221999999425E-05 |
| Normal-vs-Female |
7.64290000000445E-05 |
| Male-vs-Female |
3.340600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.561000E-04 |
| Normal-vs-Age(41-60Yrs) |
7.77020000000128E-05 |
| Normal-vs-Age(61-80Yrs) |
7.40600000215252E-08 |
| Normal-vs-Age(81-100Yrs) |
8.974400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.516400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.823520E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.508000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.081600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.695600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.270000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.862160E-01 |
| Classical-VS-Follicular |
5.881000E-01 |
| Classical-VS-Other |
5.818000E-01 |
| Classical-VS-Normal |
2.18220000000047E-05 |
| Tall-VS-Follicular |
1.560590E-01 |
| Tall-VS-Other |
2.644400E-01 |
| Tall-VS-Normal |
2.044600E-04 |
| Follicular-VS-Other |
8.315800E-01 |
| Follicular-VS-Normal |
8.418700E-03 |
| Other-VS-Normal |
2.573000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.26940000000498E-05 |
| Normal-vs-N1 |
7.032600E-04 |
| N0-vs-N1 |
9.299200E-01 |
|
|
